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Background. Variation in Clostridium difficile infection (CDI) rates between healthcare institutions suggests overall incidence 
could be reduced if the lowest rates could be achieved more widely.
Methods. We used whole-genome sequencing (WGS) of consecutive C. difficile isolates from 6 English hospitals over 1 year 
(2013–14) to compare infection control performance. Fecal samples with a positive initial screen for C. difficile were sequenced. 
Within each hospital, we estimated the proportion of cases plausibly acquired from previous cases.
Results. Overall, 851/971 (87.6%) sequenced samples contained toxin genes, and 451 (46.4%) were fecal-toxin-positive. Of 652 
potentially toxigenic isolates >90-days after the study started, 128 (20%, 95% confidence interval [CI] 17–23%) were genetically 
linked (within ≤2 single nucleotide polymorphisms) to a prior patient’s isolate from the previous 90 days. Hospital 2 had the fewest 
linked isolates, 7/105 (7%, 3–13%), hospital 1, 9/70 (13%, 6–23%), and hospitals 3–6 had similar proportions of linked isolates (22–
26%) (P ≤ .002 comparing hospital-2 vs 3–6). Results were similar adjusting for locally circulating ribotypes. Adjusting for hospital, 
ribotype-027 had the highest proportion of linked isolates (57%, 95% CI 29–81%). Fecal-toxin-positive and toxin-negative patients 
were similarly likely to be a potential transmission donor, OR = 1.01 (0.68–1.49). There was no association between the estimated 
proportion of linked cases and testing rates.
Conclusions. WGS can be used as a novel surveillance tool to identify varying rates of C. difficile transmission between institu-
tions and therefore to allow targeted efforts to reduce CDI incidence.
Keywords. infection control; Clostridium difficile; whole-genome sequencing; transmission; surveillance.
 
Preventing Clostridium difficile infection (CDI) is a pri-
ority for infection control teams, as it remains a major 
healthcare-associated infection; although the incidence of 
healthcare-associated CDI in the United Kingdom has fallen 
to 1.5 per 10 000 inpatient bed-days [1], rates across Europe 
range from 0.7 to 28.7/10 000 bed-days [2], and there were an 
estimated 293 000 healthcare-associated cases in the United 
States in 2011 [3].
Variation in CDI incidence across countries and between 
healthcare institutions [4] suggests overall incidence could 
be reduced if the lowest rates could be achieved more widely. 
Surveillance programs [5] and penalties for healthcare institutions 
[6] have been implemented to promote reductions. However, 
robustly identifying the best performing institutions is challeng-
ing. Variations in true incidence can arise from differences in 
patient risk factors or locally circulating strains. However, testing 
strategy also influences reported incidence; reported CDI inci-
dence is associated with testing rates [2]. With low testing rates, 
CDI ascertainment is likely to be suboptimal. Conversely, high 
testing rates may lead to overdiagnosis, for example, from test-
ing C. difficile colonized patients, who do not have CDI but may 
have diarrhea of another cause. The lack of a universally accepted 
objective CDI case definition means that robust comparisons of 
infection rates between institutions should ideally also consider 
independent measures of which patients are being tested to assess 
the comparability of differing testing strategies [7].
Additionally, assessing potential sources of healthcare- 
attributed CDI cases [8] is complex, requiring differentia-
tion between lapses in infection control around symptomatic 
cases or more generally, deviation from optimal antimicrobial 
stewardship, and external factors, for example, the food chain. 
Healthcare exposure increases the risk of C. difficile acquisition; 
both CDI and colonization increase during hospital stay [9]. 
However, despite this strong association, studies using whole-ge-
nome sequencing (WGS) [10–12] and other genotyping 
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schemes [13–15] have shown that, in endemic settings with 
standard infection control, only the minority of infections are 
likely to have been acquired from other hospitalized CDI cases. 
However, the extent to which this proportion of linked cases var-
ies between hospitals is unknown. Furthermore, such potential 
variance in linkage rates could identify a potentially preventable 
group of CDIs.
We investigated variation in the proportion of linked cases 
using WGS of consecutive C. difficile isolates from 6 hospitals 
in England and explored whether this could be used to assess 
their infection control effectiveness, by assessing the propor-
tion of cases plausibly acquired from (linked to) previous cases.
METHODS
Samples and Settings
Hospitals in England are recommended to store frozen aliquots 
of C. difficile–positive fecal samples for 12 months [16]. Stored 
consecutive hospital and community diarrheal samples submit-
ted for routine C. difficile testing at 6 hospital laboratories were 
studied, including a tertiary referral center and teaching hospi-
tal, and 5 district general hospitals serving a mix of urban and 
rural populations (see Supplement). Samples were obtained for 
a one-year period at each hospital between January 2013 and 
October 2014. Results were anonymized by assigning a comput-
er-generated random identifier, hospital 1 to hospital 6.
Each hospital used the United Kingdom-recommended 
2-stage C. difficile testing algorithm [17]. Hospital 1 used toxin 
gene polymerase chain reaction (PCR) as a screening test, hos-
pital 2 both glutamate dehydrogenase (GDH) enzyme immu-
noassay (EIA) and toxin gene PCR as a combined screening 
test, and hospitals 3–6 a GDH screen. Screen-positive sam-
ples underwent confirmatory fecal-toxin EIA testing. Screen-
positive, fecal-toxin-positive patients were regarded as having 
CDI. Toxin gene PCR was also performed as a third-line test on 
all GDH-positive samples at hospitals 3 and 6, and on samples 
from inpatients at hospital 5. PCR-positive, fecal-toxin-negative 
patients, with a clinical syndrome in keeping with CDI, were 
regarded as potential cases for treatment and infection control 
purposes.
All screen-positive fecal samples were sent to Leeds General 
Infirmary microbiology laboratory, United Kingdom (except 
hospital 2, which submitted isolates and excluded toxin EIA-
negative/PCR-negative samples), where they underwent 
selective culture for C.  difficile [18] and capillary electropho-
resis ribotyping [19]. Individual patient consent for use of 
anonymized bacterial isolates was not required.
Sequencing
DNA was extracted from subculture of a single colony from 
each culture-positive sample and sequenced using Illumina 
HiSeq2500. Sequence data were processed as previously (see 
Supplement) [10, 20], mapping sequenced reads to the C. diffi-
cile 630 reference genome [21]. Sequences were compared using 
single-nucleotide polymorphisms (SNPs) between sequences 
obtained from maximum-likelihood phylogenies [22], cor-
rected for recombination [23]. Potentially toxigenic strains 
were identified as those containing toxin genes using BLAST 
searches of de novo [24] assemblies.
Analysis
For each sample, only the hospital, collection date, and fecal-
toxin EIA result were known; no further epidemiological data 
were available. Within each hospital, sequences were compared 
with all sequences from samples obtained in the prior 90 days. 
Samples from the community and hospital were included to 
increase the chance of identifying transmission events occur-
ring in hospital but leading to CDI onset after discharge. From 
previous estimates of C. difficile evolution and within-host 
diversity [10, 25, 26], ≤2 SNPs are expected between isolates 
linked by transmission within 90 days. Therefore, where ≥1 
prior sequences within ≤2 SNPs were identified, a case was con-
sidered to have been potentially acquired from another case. A 
90 day threshold for linking cases was chosen assuming that 
cases were rapidly treated and infectiousness declined, and that 
subsequent cases related by direct transmission occurred within 
incubation periods implied by surveillance definitions [8] and 
previous studies [13]. As the sources of cases occurring at the 
start of the study may themselves have been sampled before the 
study started, the proportion of cases linked to a prior case was 
only calculated for cases occurring after the first 90 days, with 
cases in the first 90 days included only as potential sources for 
subsequent cases.
Two differing case definitions were considered. Initially, all 
patients with culture-positive potentially toxigenic C.  diffi-
cile were considered “cases” to capture possible transmission 
events involving potentially toxigenic C.  difficile irrespective 
of fecal-toxin status. The analysis was then repeated restricted 
only to fecal-toxin-positive CDI cases. For comparisons with 
previously published data, the same definition and analysis 
approach was applied to fecal-toxin-positive CDI cases occur-
ring within 90 days in Oxford (September 2007 to December 
2010, split by calendar year) [10] and Leeds (August 2010 to 
April 2012) [11].
Risk Factor Analysis
Univariate logistic regression was used to determine whether 
a case’s toxin status affected the risk of it being genetically 
related to a prior case, that is, potentially acquired from 
another case. Similarly, logistic regression was used to deter-
mine whether a case’s fecal-toxin status affected the risk of 
it being genetically linked to a subsequent case, that is, to 
assess the relative infectiousness of fecal-toxin-positive and 
toxin-negative patients.
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To assess whether the locally circulating strain mix affected 
transmission estimates, hospital-specific estimates were 
adjusted for ribotype using multivariate logistic regression (see 
Supplement).
Simulations
To estimate the impact of missing data (as not all sampled cases 
were sequenced at some hospitals), we simulated transmission at 
a theoretical hospital. We subsampled simulated cases and cal-
culated the change in the percentage of cases linked to a prior 
case as the proportion of missing samples increases (details in 
Supplement).
RESULTS
Consecutive samples sent for C. difficile testing at 6 hospitals 
were studied for 12 months (Table 1). In total, 1052/1098 (96%) 
of GDH/toxin-PCR screen-positive samples were available: 
95/98 (97%) at hospital 1, 144/178 (81%) at hospital 2, 118/127 
(93%) at hospital 5 and otherwise 100%. 974/1052 (93%) avail-
able samples were confirmed as C. difficile on culture. For the 
5 hospitals with available testing data, 887/21 539 (4.1%) of 
samples submitted for testing were culture-positive (Table 1); 
971/974 (99.7%) culture-positive samples were successfully 
sequenced. Of sequenced culture-positive samples, 451/971 
(46.4%) were EIA fecal-toxin-positive, 35–71% by hospital. By 
contrast, 851/971 (87.6%) were potentially toxigenic, that is, had 
toxin genes detected via sequence data. Hence, 400/851 (47.0%) 
samples containing potentially toxigenic C. difficile did not have 
fecal-toxin detected. In the 971 sequenced isolates, the most 
common ribotypes identified were 014, 015, 005, 002, 020, and 
078 (Table 2). Ribotype-027(NAP1/ST-1) only accounted for 16 
(2%) cases.
Relatedness to Prior Cases
The proportion of cases plausibly linked to a prior case by recent 
transmission varied by hospital. Of 851 sequenced potentially 
toxigenic cases, all were considered as potential sources of infec-
tion, but only the 652 obtained after the first 90 days of sampling 
at each hospital were assessed for linkage to a previous case. 
Across the 6 hospitals, 128/652 (20%, 95% confidence interval 
[CI] 17–23%) potentially toxigenic cases were genetically linked 
to a prior case from the previous 90  days. Hospital 2 had the 
fewest cases linked to a prior case, 7/105 (7%, 3–13%), hospital 1 
had an intermediate number, 9/70 (13%, 6–23%), and hospitals 
3–6 had similar numbers of linked cases, 37/153 (24%, 18–32%), 
32/134 (24%, 17–32%), 18/76 (24%, 15–35%), and 25/113 (22%, 
15–31%), respectively. Hospital 2 had significantly fewer linked 
cases than hospitals 3–6 (P  ≤  .002), with weaker evidence for 
lower rates in hospital 1 than hospitals 3, 4, and 5 (P = .05, .07, .09, 
respectively). Overall, 48/128 (38%) of potential transmission 
recipients were fecal-toxin-negative (11–68% across hospitals, 
Figure 1A). Fecal-toxin detection in a recipient was associated Ta
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with increased odds of having a potential transmission donor, 
odds ratio 1.67 (95% CI 1.12–2.48, P = .01).
In total, 59/128 (46%) putative transmission recipi-
ents were only linked to ≥1 fecal-toxin-positive potential 
donors, 50 (39%) to only fecal-toxin-negative donors, and 
19 (15%) to both toxin-positive and toxin-negative donors. 
Considering the 667 cases occurring in the first 270 days at 
each hospital, that is, the cases with an opportunity to trans-
mit to a sampled case within the next 90 days, 120 (18%) were 
potential donors. Fecal-toxin-positive and -negative cases 
were similarly infectious: the odds ratio for a fecal-toxin- 
positive case, compared to a fecal-toxin-negative case, being 
a potential transmission donor was 1.01 (95% CI 0.68–1.49, 
P = .97).
When only considering transmission to and from fecal- 
toxin-positive cases, fewer cases were genetically linked to a 
previous case within 90 days, 51/335 (15%, 95% CI 12–20%). 
We observed a different “ranking” of hospitals compared with 
the above analysis of linkage rates based on potentially toxi-
genic isolate-positive patients: hospital 3 had the greatest pro-
portion of fecal-toxin-positive cases genetically related to a 
prior fecal-toxin-positive case, 31% (22–41%), and hospital 6 
the lowest, 0% (0–9%) (Figure 1B).
Results were similar to those for all potentially toxigenic C. 
difficile (Figure 1A) if all C. difficile sequences, nontoxigenic 
as well as potentially toxigenic, were considered (Figure 1C). 
Considering only nontoxigenic isolates, very similarly to 
potentially toxigenic isolates, 19/96 (20%, 95% CI 12–29%) 
were genetically linked to a prior patient isolate from the pre-
vious 90 days.
There was no evidence that the number of linked cases varied 
during the study at any hospital (Figure 1D). Because different 
numbers of sequences were obtained from the different hospi-
tals, we investigated how this affected the estimated proportions 
of cases linked to a prior case. Estimated proportions of linked 
cases were relatively stable once approximately 50 cases had 
been sequenced (Figure 2).
Impact of Testing Frequency
The proportion of originally tested samples that were stored 
and then culture-positive was similar across the 5 hospitals 
with testing data, 3.8%–4.3% (P =  .89, Table 1). In contrast, 
testing rates ranged from 98 to 239 samples per 10 000 bed-
days. There was no association between the estimated pro-
portion of cases linked to a previous case within 90  days 
and testing rates (P =  .19 for all potentially toxigenic cases, 
Figure  3A, and P  =  .60 for fecal-toxin-positive cases only, 
Figure  3B). For comparison, Figure  3B also displays rates 
of linked cases for previously published data from Oxford 
and Leeds.
Table 2. Ribotype Distribution by Hospital and Proportion of Cases Genetically Linked to a Previous Case by Ribotype
All Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Hospital 6
Linked to a Previous Case Within 
≤2 SNPs and ≤90 Days
Ribotype n % n % N % n % n % n % N %
n, >90 
Days Into 
Study n, Linked
% 
Linked
014 98 10 12 14 18 13 19 9 26 11 10 9 13 7 75 15 20
015 89 9 13 15 14 10 13 6 16 7 18 16 15 8 67 8 12
005 80 8 6 7 9 6 16 8 25 10 10 9 14 8 61 7 11
002 77 8 8 9 11 8 15 7 14 6 6 5 23 13 54 14 26
020 62 6 2 2 11 8 21 10 15 6 5 4 8 4 46 9 20
078 53 5 6 7 9 6 11 5 8 3 6 5 13 7 41 8 20
039 45 5 0 0 5 3 8 4 26 11 1 1 5 3 35 11 31
023 35 4 8 9 4 3 7 3 8 3 3 3 5 3 28 6 21
001 29 3 4 5 1 1 13 6 5 2 3 3 3 2 24 8 33
012 27 3 1 1 5 3 3 1 9 4 7 6 2 1 22 11 50
026 26 3 1 1 1 1 11 5 5 2 1 1 7 4 19 1 5
010 23 2 0 0 0 0 6 3 16 7 0 0 1 1 18 2 11
011 19 2 2 2 10 7 2 1 1 0 2 2 2 1 16 2 13
087 19 2 0 0 0 0 4 2 2 1 7 6 6 3 18 9 50
050 16 2 4 5 1 1 3 1 4 2 2 2 2 1 13 2 15
013 16 2 2 2 4 3 3 1 0 0 6 5 1 1 12 1 8
027 16 2 4 5 2 1 4 2 1 0 0 0 5 3 12 7 58
003 15 2 1 1 2 1 1 0 5 2 0 0 6 3 14 3 21
017 15 2 1 1 0 0 2 1 6 2 1 1 5 3 10 4 40
Other 211 22 12 14% 36 25 44 21 53 22 24 21 42 24 163 19 12
Total 971 100% 87 100% 143 100% 206 100 245 100 112 100 178 100 748 147 20
Abbreviation: SNP, single-nucleotide polymorphism.
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Adjustment for Ribotype
After adjustment for locally circulating ribotypes, estimates of 
the proportion of potentially toxigenic cases related to a pre-
vious potentially toxigenic case within ≤2 SNPs and ≤90 days 
remained largely unchanged (Figure 4A). Using the same model, 
per-ribotype estimates for the proportion of related cases, 
adjusted for differences across hospitals, showed more variation 
(Figure 4B, Table 2 for unadjusted proportions). Ribotype-027 
had significantly more related cases (adjusted proportion, 57%, 
95% CI 29–81%, n = 12) than the comparison group of all other 
ribotypes (11%, 7–18%, P = .002, n = 124), as did ribotype-002 
(25%, 15–38%, P = .04, n = 53), 012 (50%, 29–71%, P = .001, n 
= 22), and 087 (44%, 23–67%, P = .005, n = 18).
Adjustment for Completeness of Testing
As only 144/178 (81%) of GDH-positive samples at hospital 2 
were retrievable for culture we assessed the likely impact of these 
missing samples on the estimated proportion of linked cases by 
simulating transmission and sampling at a theoretical hospital 
(Figure S1). As sampling becomes increasingly less complete, 
the estimated proportion of linked cases declines proportional 
to the probability of a case being sampled. Applying our sim-
ulation to hospital 2 provides a revised estimate of 8% of cases 
being linked to a prior case (see Supplement for details).
DISCUSSION
Here, we demonstrate the value of WGS as a tool to estimate 
different rates of C. difficile transmission across institutions. 
Sequencing consecutive C.  difficile isolates from routine 
testing over one year, we found transmission rates varied 
between 6 hospitals. Considering all patients with poten-
tially toxigenic C. difficile, irrespective of fecal-toxin status, 
in the best performing hospital only 7% of patients’ isolates 
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Figure 1. Proportion of cases linked to a previous case by hospital. A, Proportion of potentially toxigenic cases linked to a previous potentially toxigenic case, by hospital 
and recipient fecal-toxin status. B, Proportion of fecal-toxin-positive cases linked to a previous fecal-toxin-positive case. C, Proportion of all Clostridium difficile (potentially 
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were sufficiently genetically related to a previous isolate 
from another patient to support transmission (8% adjusting 
for incomplete sampling). By contrast, approximately 3–4-
fold more isolates (22–26%) were related in 4 of the other 
hospitals. These results remained similar after adjusting for 
the locally circulating strains.
Restricting to only patients with fecal-toxin-positive CDI, 
we confirmed previous findings that only a minority of CDI 
cases arise from contact with another symptomatic case: 35% 
in Oxford [10], 35% in Leeds [11], and 37% of ribotype-027 
cases in Liverpool [12], were genetically linked to a previous 
case, with only a subset of these cases sharing time and space 
on the same hospital ward. Applying the criteria for linking 
cases used in the present study to the Oxford and Leeds data 
sets, 38% of cases in Oxford were linked to a previous case 
in 2008 falling to 19% in 2010, and 30% of cases were simi-
larly linked in Leeds. Across the 6 study hospitals, serving a 
range of populations, toxin-positive CDI linkage rates were 
all <15% with the exception of hospital 3, where 31% of cases 
were linked. It is likely the lower linkage rates in the current 
study in part reflect the falling incidence of ribotype-027 
[11], associated with more onward transmission in this study, 
likely as a result of national fluoroquinolone restriction [27] 
but may also represent changes in infection prevention and 
control practice.
Our findings also support the recently reported role in trans-
mission of GDH-positive patients with toxigenic C. difficile, but 
no detected fecal-toxin [28]. By sequencing all GDH-positive 
cases, we were able to compare the probability of fecal-tox-
in-positive and toxin-negative patients being potential sources 
of transmission, that is, having C. difficile genetically linked to 
a subsequent C. difficile isolate in another patient. Fecal-toxin-
negative patients were similarly infectious to fecal-toxin-positive 
patients: fecal-toxin status did not affect the odds of being a 
potential transmission source. Strategies to identify and insti-
tute infection control measures around patients with potentially 
toxigenic C. difficile without detected fecal-toxin are therefore 
likely to reduce overall CDI incidence, although may be more 
costly, for example if toxin gene PCR is used as an initial screen 
rather than GDH EIA. Toxin-positive patients, that is, CDI 
cases, were more likely to have an identified potential trans-
mission donor, than toxin-negative patients. This is in keeping 
with previous observations that recent C.  difficile acquisition 
is associated with increased risk of disease, whereas long-term 
carriage is relatively protective [29].
It is likely that differing clinical CDI testing thresholds 
applied across the study hospitals, despite each being guided by 
national recommendations; notably, testing rates varied more 
than 2-fold between hospitals (98–239 tests/10 000 bed-days). 
However, despite this variation, the overall proportion of sam-
ples tested that were C. difficile culture-positive was very simi-
lar across hospitals (~4%). These 2 findings combined resulted 
in varying rates of potentially toxigenic C.  difficile isolation, 
4.2–8.2/10 000 bed-days, and varying (fecal-toxin-positive) 
CDI rates, 1.8–5.7/10 000 bed-days. As the proportion of sam-
ples that were C. difficile culture-positive was close to reported 
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community asymptomatic C. difficile colonization rates (~4%), 
and lower than reported colonization rates in asymptomatic 
hospital inpatients, (~10%) [30], it is possible that the higher 
reported CDI rates in some study hospitals may reflect over-
ascertainment; independent assessment of which symptomatic 
patients are tested for CDI would be required to resolve this 
with certainty [7]. As designed, the study did not measure the 
extent of transmission involving asymptomatic patients, and 
therefore it is likely that not all hospital-associated transmission 
is captured. However, as this was the case for all hospitals, com-
parisons can still be made between hospitals and with previous 
studies investigating symptomatic patients.
Interestingly, we did not find any evidence of a relationship 
between rates of C. difficile testing and proportions of cases that 
could be linked to a previous case. Differing sampling/testing 
will likely mean the study populations at each hospital varied, 
for example with some institutions potentially more likely to 
include milder CDI cases than others. It should also be noted 
that differences in the population sampled by a particular test-
ing strategy may affect the proportion of cases linked differently 
to incomplete sampling of a given population. We quantified the 
impact of the latter through simulation. Unfortunately, incom-
plete sampling could appear very similar to the impact of good 
infection control, as both results in low proportions of linked 
cases. One study limitation is that we only sequenced 81% 
GDH-positive samples at hospital 2. However, we demonstrate 
it may be possible to adjust for incomplete sampling, providing 
missed cases as assumed missing at random, and the number of 
onward transmissions from each case was random.
Both a limitation and a strength of our approach is that it 
relies only on sequencing laboratory samples and sampling 
dates. We demonstrate this allows comparative hospital surveil-
lance with very limited, and no personal, sensitive or confiden-
tial, data. However, without ward admission and patient contact 
data, it is possible some genetically linked cases do not repre-
sent direct transmission from other cases. Genetic links might 
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also arise through indirect healthcare-associated transmission 
via unsampled hosts or the hospital environment. Additionally, 
a minority of cases, without healthcare exposure in the last 
90 days, may still have been genetically linked. However, there 
is no obvious reason why genetically related community C. dif-
ficile exposures, and therefore the proportion of such cases 
linked, should vary across England at a population level, even 
if other CDI risk factors do vary geographically, for example, 
antimicrobial use. Therefore, although we analyze transmission 
within the populations served by each hospital, as most CDI 
cases have recent healthcare exposure, the overall proportion of 
linked cases is still likely to be a reasonable combined indicator 
of infection control performance around cases and more gener-
ally. Without patient-level identifiers some repeat tests from the 
same patient may have been wrongly assigned as transmission 
events; however, we anticipate this was uncommon; repeat test-
ing within 28 days is discouraged in national guidelines [17], 
and such samples are frequently not routinely processed.
Our method of comparing infection control performance 
depends on culturing C. difficile, which is not routinely under-
taken, and on sequencing at least 6  months of samples, at 
around US$100 per sample. However, if samples are stored, as 
recommended in England, C.  difficile could be cultured and 
sequenced retrospectively if increased incidence was noted 
and then continued prospectively to monitor the impact of any 
interventions. The cost-effectiveness of such an approach needs 
further evaluation.
In summary, here we present a novel method that ena-
bles assessment of the extent of hospital-acquired infection 
transmission within healthcare institutions. This approach 
revealed differences in CDI transmission rates across 6 
English hospitals. It demonstrates the potential of whole-ge-
nome sequencing as a nationwide tool to identify institutions 
with excellent and also suboptimal infection control and 
therefore has the potential to allow targeted efforts to reduce 
CDI incidence.
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